Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials - PubMed (original) (raw)
Meta-Analysis
. 2010 Nov 13;376(9753):1670-81.
doi: 10.1016/S0140-6736(10)61350-5. Epub 2010 Nov 8.
C Baigent, L Blackwell, J Emberson, L E Holland, C Reith, N Bhala, R Peto, E H Barnes, A Keech, J Simes, R Collins
Collaborators, Affiliations
- PMID: 21067804
- PMCID: PMC2988224
- DOI: 10.1016/S0140-6736(10)61350-5
Meta-Analysis
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
Cholesterol Treatment Trialists’ (CTT) Collaboration et al. Lancet. 2010.
Abstract
Background: Lowering of LDL cholesterol with standard statin regimens reduces the risk of occlusive vascular events in a wide range of individuals. We aimed to assess the safety and efficacy of more intensive lowering of LDL cholesterol with statin therapy.
Methods: We undertook meta-analyses of individual participant data from randomised trials involving at least 1000 participants and at least 2 years' treatment duration of more versus less intensive statin regimens (five trials; 39 612 individuals; median follow-up 5·1 years) and of statin versus control (21 trials; 129 526 individuals; median follow-up 4·8 years). For each type of trial, we calculated not only the average risk reduction, but also the average risk reduction per 1·0 mmol/L LDL cholesterol reduction at 1 year after randomisation.
Findings: In the trials of more versus less intensive statin therapy, the weighted mean further reduction in LDL cholesterol at 1 year was 0·51 mmol/L. Compared with less intensive regimens, more intensive regimens produced a highly significant 15% (95% CI 11-18; p<0·0001) further reduction in major vascular events, consisting of separately significant reductions in coronary death or non-fatal myocardial infarction of 13% (95% CI 7-19; p<0·0001), in coronary revascularisation of 19% (95% CI 15-24; p<0·0001), and in ischaemic stroke of 16% (95% CI 5-26; p=0·005). Per 1·0 mmol/L reduction in LDL cholesterol, these further reductions in risk were similar to the proportional reductions in the trials of statin versus control. When both types of trial were combined, similar proportional reductions in major vascular events per 1·0 mmol/L LDL cholesterol reduction were found in all types of patient studied (rate ratio [RR] 0·78, 95% CI 0·76-0·80; p<0·0001), including those with LDL cholesterol lower than 2 mmol/L on the less intensive or control regimen. Across all 26 trials, all-cause mortality was reduced by 10% per 1·0 mmol/L LDL reduction (RR 0·90, 95% CI 0·87-0·93; p<0·0001), largely reflecting significant reductions in deaths due to coronary heart disease (RR 0·80, 99% CI 0·74-0·87; p<0·0001) and other cardiac causes (RR 0·89, 99% CI 0·81-0·98; p=0·002), with no significant effect on deaths due to stroke (RR 0·96, 95% CI 0·84-1·09; p=0·5) or other vascular causes (RR 0·98, 99% CI 0·81-1·18; p=0·8). No significant effects were observed on deaths due to cancer or other non-vascular causes (RR 0·97, 95% CI 0·92-1·03; p=0·3) or on cancer incidence (RR 1·00, 95% CI 0·96-1·04; p=0·9), even at low LDL cholesterol concentrations.
Interpretation: Further reductions in LDL cholesterol safely produce definite further reductions in the incidence of heart attack, of revascularisation, and of ischaemic stroke, with each 1·0 mmol/L reduction reducing the annual rate of these major vascular events by just over a fifth. There was no evidence of any threshold within the cholesterol range studied, suggesting that reduction of LDL cholesterol by 2-3 mmol/L would reduce risk by about 40-50%.
Funding: UK Medical Research Council, British Heart Foundation, European Community Biomed Programme, Australian National Health and Medical Research Council, and National Heart Foundation.
Copyright © 2010 Elsevier Ltd. All rights reserved.
Figures
Figure 1
Effects on any major vascular event in each study In the left panel, unweighted rate ratios (RRs) for each trial of the comparison of first event rates between randomly allocated treatment groups are plotted along with 99% CIs. Trials are ordered according to the absolute reduction in LDL cholesterol (LDL-C) at 1 year within each type of trial comparison (more vs less statin and statin vs control). In the right panel, rate ratios are weighted per 1·0 mmol/L LDL cholesterol difference at 1 year. Subtotals and totals with 95% CIs are shown by open diamonds.
Figure 2
Effects on each type of major vascular event In the left panel, unweighted rate ratios (RRs) are plotted for each comparison of first event rates between randomly allocated treatment groups. In the right panel, RRs are weighted per 1·0 mmol/L LDL cholesterol (LDL-C) difference at 1 year. RRs are shown with horizontal lines denoting 99% CIs or with open diamonds denoting 95% CIs. MI=myocardial infarction. CHD=coronary heart disease. CABG=coronary artery bypass graft. PTCA=percutaneous transluminal coronary angioplasty.
Figure 3
Effects on major vascular events per 1·0 mmol/L reduction in LDL cholesterol, by baseline prognostic factors Rate ratios (RRs) are plotted for each comparison of first event rates between treatment groups, and are weighted per 1·0 mmol/L LDL cholesterol (LDL-C) difference at 1 year. Missing data are not plotted. RRs are shown with horizontal lines denoting 99% CIs or with open diamonds showing 95% CIs. CHD=coronary heart disease. GFR=glomerular filtration rate.
Figure 4
Effects on major vascular events per 1·0 mmol/L reduction in LDL cholesterol, by baseline LDL cholesterol concentration on the less intensive or control regimen Rate ratios (RRs) are plotted for each comparison of first event rates between treatment groups, and are weighted per 1·0 mmol/L LDL cholesterol (LDL-C) difference at 1 year. Analyses were done with trial-specific and subgroup-specific LDL weights for each baseline LDL cholesterol category. Missing data are not plotted. RRs are shown with horizontal lines denoting 99% CIs or with open diamonds showing 95% CIs.
Figure 5
Effects on cause-specific mortality per 1·0 mmol/L reduction in LDL cholesterol Rate ratios (RRs) are plotted for each comparison of first event rates between treatment groups and are weighted per 1·0 mmol/L LDL cholesterol (LDL-C) difference at 1 year. RRs are shown with horizontal lines denoting 99% CIs or with open diamonds showing 95% CIs. CHD=coronary heart disease.
Figure 6
Effects on site-specific cancer incidence per 1·0 mmol/L reduction in LDL cholesterol Rate ratios (RRs) are plotted for each comparison of first event rates between treatment groups and are weighted per 1·0 mmol/L LDL cholesterol (LDL-C) difference at 1 year. RRs are shown with horizontal lines denoting 99% CIs or with open diamonds showing 95% CIs. Analyses are of first cancers, subdivided by site: gastrointestinal (International Classification of Disease codes version 9 140–159); genitourinary (179–189); respiratory (160–163,165); female breast (174); haematological (200–208); melanoma (172); other/unknown site (other cancers with codes 140–172, 174–209, plus deaths with codes 173, 210–239).
Comment in
- Is intensive LDL-cholesterol lowering beneficial and safe?
Cheung BM, Lam KS. Cheung BM, et al. Lancet. 2010 Nov 13;376(9753):1622-4. doi: 10.1016/S0140-6736(10)61545-0. Epub 2010 Nov 8. Lancet. 2010. PMID: 21067806 No abstract available. - Efficacy and safety of more intensive lowering of LDL cholesterol.
Bonovas S, Nikolopoulos G, Sitaras NM. Bonovas S, et al. Lancet. 2011 Feb 26;377(9767):715; author reply 715-6. doi: 10.1016/S0140-6736(11)60261-4. Lancet. 2011. PMID: 21353894 No abstract available. - Efficacy and safety of more intensive lowering of LDL cholesterol.
Giral P, Moulin P, Rosenbaum D. Giral P, et al. Lancet. 2011 Feb 26;377(9767):715; author reply 715-6. doi: 10.1016/S0140-6736(11)60262-6. Lancet. 2011. PMID: 21353895 No abstract available. - ACP journal club. Meta-analysis: more intensive statin therapy prevents major vascular events.
Smith DA. Smith DA. Ann Intern Med. 2011 May 17;154(10):JC5-03. doi: 10.7326/0003-4819-154-10-201105170-02003. Ann Intern Med. 2011. PMID: 21576521 No abstract available. - Statine in der Primärprävention, ja oder nein? - Metaanalysen mit unterschiedlichen Resultaten.
Woitzek K. Woitzek K. Praxis (Bern 1994). 2011 Jul 6;100(14):869-71. doi: 10.1024/1661-8157/a000596. Praxis (Bern 1994). 2011. PMID: 21732302 German. No abstract available.
Similar articles
- The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
Cholesterol Treatment Trialists' (CTT) Collaborators; Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. Cholesterol Treatment Trialists' (CTT) Collaborators, et al. Lancet. 2012 Aug 11;380(9841):581-90. doi: 10.1016/S0140-6736(12)60367-5. Epub 2012 May 17. Lancet. 2012. PMID: 22607822 Free PMC article. - Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.
Cholesterol Treatment Trialists' Collaboration. Cholesterol Treatment Trialists' Collaboration. Lancet. 2019 Feb 2;393(10170):407-415. doi: 10.1016/S0140-6736(18)31942-1. Lancet. 2019. PMID: 30712900 Free PMC article. - Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Baigent C, et al. Lancet. 2005 Oct 8;366(9493):1267-78. doi: 10.1016/S0140-6736(05)67394-1. Epub 2005 Sep 27. Lancet. 2005. PMID: 16214597 - Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.
Law MR, Wald NJ, Rudnicka AR. Law MR, et al. BMJ. 2003 Jun 28;326(7404):1423. doi: 10.1136/bmj.326.7404.1423. BMJ. 2003. PMID: 12829554 Free PMC article. Review. - Interpretation of the evidence for the efficacy and safety of statin therapy.
Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Collins R, et al. Lancet. 2016 Nov 19;388(10059):2532-2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8. Lancet. 2016. PMID: 27616593 Review.
Cited by
- First manifestation of cardiovascular disease according to age and sex in a Mediterranean country.
Ortega E, Genua I, Mata-Cases M, Roqué M, Vlacho B, Real Gatius J, Franch-Nadal J, Mauricio D. Ortega E, et al. Front Cardiovasc Med. 2024 Sep 17;11:1403363. doi: 10.3389/fcvm.2024.1403363. eCollection 2024. Front Cardiovasc Med. 2024. PMID: 39355347 Free PMC article. - Effectiveness of Coenzyme Q10 Supplementation in Statin-Induced Myopathy: A Systematic Review.
Ahmad K, Manongi NJ, Rajapandian R, Moti Wala S, Al Edani EM, Samuel EA, Arcia Franchini AP. Ahmad K, et al. Cureus. 2024 Aug 31;16(8):e68316. doi: 10.7759/cureus.68316. eCollection 2024 Aug. Cureus. 2024. PMID: 39350827 Free PMC article. Review. - Role of the screening with coronary computed tomography angiography on lipid management and risk factors control in an asymptomatic Chinese population: a community-based, parallel-group, open-label, randomized clinical trial (RESPECT2).
Guo X, Li J, Zhu Y, Li Y, Jiang J, Zuo R, Xu W, Ma J, Li C, Yang J, Liu Y, Zhao M, Tian D, Wang X, Sun J, Wu B, Wang C, Jiang P, Zhang J, Zhong J, Zhou C, Yi D, Bao X, Cai J, Chen Y, Cheng X, Gong H, Wei Y, Liu Y, Zhang LJ. Guo X, et al. Trials. 2024 Sep 30;25(1):635. doi: 10.1186/s13063-024-08469-z. Trials. 2024. PMID: 39350195 Free PMC article. - Assessing Performance of Martins's and Sampson's Formulae for Calculation of LDL-C in Indian Population: A Single Center Retrospective Study.
Sankanagoudar S, Tomo S, Syiemlieh A, Sharma PP, Banerjee M, Sharma P. Sankanagoudar S, et al. Indian J Clin Biochem. 2024 Oct;39(4):579-585. doi: 10.1007/s12291-023-01142-3. Epub 2023 Jul 7. Indian J Clin Biochem. 2024. PMID: 39346721 - Quantifying the 'distance to LDC-goal' in patients at very high cardiovascular risk with hyperlipidaemia in Germany: a retrospective claims database analysis.
Stach K, Richter H, Fraass U, Stein A. Stach K, et al. Ther Adv Cardiovasc Dis. 2024 Jan-Dec;18:17539447241277402. doi: 10.1177/17539447241277402. Ther Adv Cardiovasc Dis. 2024. PMID: 39340274 Free PMC article.
References
- Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278. - PubMed
- Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–1389. - PubMed
- Shepherd J, Cobbe SM, Ford I. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307. - PubMed
- Sacks FM, Pfeffer MA, Moyé LA. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001–1009. - PubMed
- The Post Coronary Artery Bypass Graft Trial Investigators The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med. 1997;336:153–162. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- G0701732/MRC_/Medical Research Council/United Kingdom
- MC_U137686849/MRC_/Medical Research Council/United Kingdom
- MC_U137686853/MRC_/Medical Research Council/United Kingdom
- BHF_/British Heart Foundation/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical